Prograf and Pyelocaliectasis - a phase IV clinical study of FDA data

Summary:

Pyelocaliectasis is reported as a side effect among people who take Prograf (tacrolimus), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Myfortic, and have Immunodeficiency disorders.

The phase IV clinical study analyzes which people have Pyelocaliectasis when taking Prograf. It is created by eHealthMe based on reports of 41,725 people who have side effects when taking Prograf from the FDA, and is updated regularly.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 42,230 Prograf users. Check the latest studies of Prograf.

What is Pyelocaliectasis?

Pyelocaliectasis is found to be associated with 221 drugs and 295 conditions by eHealthMe. Check the latest studies of Pyelocaliectasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

41,725 people reported to have side effects when taking Prograf.
Among them, 13 people (0.03%) have Pyelocaliectasis.

Among these 13 people:

How long have people been on Prograf when they have Pyelocaliectasis? *

What is the gender of people who have Pyelocaliectasis when taking Prograf? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Pyelocaliectasis when taking Prograf? *

What are other drugs people take besides Prograf? *

What are other side effects people have besides Pyelocaliectasis? *

Renal Impairment (severely reduced kidney function): 7 people, 53.85%
Kidney Transplant Rejection: 7 people, 53.85%
Obstruction: 4 people, 30.77%
Sinusitis (inflammation of sinus): 4 people, 30.77%
Parophthalmia (inflammation of the connective tissue around the eye): 4 people, 30.77%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 4 people, 30.77%
Eyes - Bulging (swelling of eyes): 4 people, 30.77%
Eye Pain: 4 people, 30.77%
Sinus Headache (headache caused by sinus infections): 4 people, 30.77%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 30.77%

What are the existing conditions these people have? *

Immunodeficiency Disorders: 5 people, 38.46%
Oral Candidiasis (fungal infection of mouth): 4 people, 30.77%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Prograf and have Pyelocaliectasis?

- Check whether Pyelocaliectasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Prograf:

Prograf (42,230 reports)

Browse all side effects of Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pyelocaliectasis:

Pyelocaliectasis (221 drugs)

Browse all the conditions that are associated with Pyelocaliectasis:

Pyelocaliectasis (295 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Prograf) and Prograf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.